Skip to content
  • Bispecific antibody for Wet AMD/Diabetic macular edema
  • This is our next-generation treatment for those afflicted with Wet AMD/DME. These are generally diseases that gradually cause blindness in patients. Our molecule, a bispecific antibody, has been engineered to improve the current VEGF therapies already being used to treat patients effectively. By using the latest in antibody engineering, the molecule can potentially improve efficacy and also durability for patients, leading to an overall higher quality of life.
Back To Top